Thompson Davis & CO. Inc. Has $471,000 Stock Holdings in CareDx, Inc (NASDAQ:CDNA)

Thompson Davis & CO. Inc. decreased its holdings in shares of CareDx, Inc (NASDAQ:CDNA) by 15.3% in the 3rd quarter, Holdings Channel.com reports. The firm owned 15,100 shares of the company’s stock after selling 2,725 shares during the quarter. Thompson Davis & CO. Inc.’s holdings in CareDx were worth $471,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CDNA. GAMMA Investing LLC lifted its holdings in shares of CareDx by 1,021.8% during the second quarter. GAMMA Investing LLC now owns 2,210 shares of the company’s stock worth $34,000 after buying an additional 2,013 shares during the last quarter. Plato Investment Management Ltd bought a new position in CareDx during the second quarter worth $62,000. KBC Group NV bought a new position in CareDx during the third quarter worth $99,000. nVerses Capital LLC raised its stake in CareDx by 175.0% during the 3rd quarter. nVerses Capital LLC now owns 3,300 shares of the company’s stock valued at $103,000 after purchasing an additional 2,100 shares during the last quarter. Finally, Meeder Asset Management Inc. bought a new stake in CareDx in the 2nd quarter valued at $142,000.

CareDx Stock Up 2.3 %

NASDAQ CDNA opened at $22.06 on Wednesday. CareDx, Inc has a twelve month low of $7.42 and a twelve month high of $34.84. The stock has a market cap of $1.18 billion, a P/E ratio of -8.17 and a beta of 1.80. The company’s 50-day simple moving average is $26.56 and its 200 day simple moving average is $21.88.

CareDx (NASDAQ:CDNA) last released its quarterly earnings data on Monday, November 4th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.11. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The company had revenue of $82.88 million for the quarter, compared to analyst estimates of $80.04 million. During the same period in the prior year, the company posted ($0.43) EPS. The company’s revenue was up 23.4% compared to the same quarter last year. Research analysts anticipate that CareDx, Inc will post -0.7 earnings per share for the current year.

Wall Street Analyst Weigh In

CDNA has been the topic of several research reports. The Goldman Sachs Group boosted their price objective on shares of CareDx from $26.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. Wells Fargo & Company started coverage on CareDx in a research report on Tuesday, August 27th. They set an “underweight” rating and a $28.00 target price on the stock. Craig Hallum upped their price target on CareDx from $22.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, August 1st. HC Wainwright reiterated a “neutral” rating on shares of CareDx in a research report on Tuesday, October 22nd. Finally, BTIG Research lowered their price objective on CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.60.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.